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Abstract
Background: No Danish guidelines for screening of sexually transmitted infections (STIs) in women living with HIV
(WLWH) exist, except for annual syphilis testing. Drug-drug interaction between hormonal contraceptives and some
types of highly active antiretroviral therapy (HAART) occurs. We assessed prevalence of STIs, contraceptive choices
and predictors of condom use in a cohort of WLWH in Denmark.
Methods: WLWH consecutively enrolled during their outpatient visits from 2011 to 2012. Gynaecological examination
and an interview were performed at entry and 6-month follow-up. Inclusion criteria were HIV-1 infection and≥
18 years of age. Exclusion criteria were pregnancy, alcohol- or drug abuse impeding adherence to the protocol.
At entry, participants were tested (and where appropriate, treated according to guidelines) for Chlamydia
trachomatis, Neisseria gonorrhoeae, syphilis, and herpes simplex (HSV-1 and HSV-2). At follow-up, predictors of
condom use were estimated in sexually active WLWH.
Results: In total, 334 of the 1,392 eligible WLWH in Denmark were included (median age and HIV duration:
42.5 and 11.3 years). Chlamydia trachomatis was present in four individuals (1 %), and six (2 %) tested positive
for HSV-2 by PCR. None were positive for Neisseria gonorrhoeae, HSV-1 or had active syphilis. At follow-up, 252
(76 %) participated; 168 (70 %) were sexually active. Contraceptives were used by 124 (75 %); condoms were
preferred (62 %). Having an HIV-negative partner predicted condom use (adjusted OR 3.89 (95 %CI 1.49-
10.11)). In the group of participants of reproductive age without pregnancy desires 13 % used no birth-
control. Possible drug-drug interaction between hormonal contraceptives and HAART was found in 13/14
WLWH receiving both kinds of medication.
Conclusion: The prevalence of STIs in WLWH in Denmark was low. The need for annual STI screening is questionable.
Condoms were preferred contraceptives, especially in WLWH with an HIV-negative partner. In this cohort, 13 % of
WLWH of reproductive age were at risk of unintended pregnancies due to lack of birth-control. Finally, in the subgroup
of WLWH receiving both hormonal contraceptives and HAART possible drug-drug interactions could occur.
Keywords: Women living with HIV, Sexually transmitted infections, Screening, Contraceptive use, condom use,
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Background
New attitudes towards condomless sex in people living
with HIV-1 infection (PLHIV) have emerged as a result
of among others the HPTN 052 trial that found reduced
rates of sexual transmission of HIV in patients with early
initiation of highly active antiretroviral therapy
(HAART) [1] and the interim analysis of the PARTNER
study reporting zero linked HIV transmissions from
condomless sex within mixed-HIV-status couples, when
the partner living with HIV had a viral load below 200
copies/mL [2]. Accordingly, sexual HIV transmission is
thought to be negligible in patients adherent to HAART,
with a suppressed viral load, and without sexually trans-
mitted infections (STIs) [1, 2].
Increased incidences of STIs – serving as a proxy of
condomless sex, especially among men who have sex
with men (MSM) [3, 4] – are a risk to health and facili-
tate acquisition and transmission of HIV [3, 5]. Yet, data
regarding the prevalence of STIs among women living
with HIV (WLWH) are scarce [4, 5], and most existing
studies focus on women newly diagnosed with HIV [5].
Guidelines from the European Aids Clinical Society
(EACS) recommend that screening for STIs should be
offered to all sexually active PLHIV at time of HIV diag-
nosis, annually thereafter or at any time STI symptoms
are reported [6]. In Denmark, however, no guidelines for
routine STI screening in PLHIV exist, except for annual
syphilis testing [3]. Whether STI screening is needed in
WLWH is unknown.
The trend towards condemless sex yields for alternate
means of contraception. Most WLWH are of childbear-
ing potential (10;11), which makes counselling on family
planning and use of contraceptives a most relevant issue.
This article reports the first data from the Study on
HIV, cervical Abnormalities and infections in women in
Denmark (SHADE). Several gaps in evidence in caring
for WLWH have been identified such as sexual health,
gynaecological diseases and contraceptive use [7, 8]. The
aim of the present study was to evaluate the prevalence
of STIs in a cohort of WLWH and to assess whether
routine screening for STIs in WLWH in Denmark is
needed. Moreover, we describe sexual activity, contra-
ceptive choices, and predictors of condom use in a co-
hort of WLWH in Denmark with free access to
healthcare and HAART.
Methods
Setting
Denmark has a population of 5.6 million [9] and an esti-
mated HIV prevalence among adults of 0.1 % [10]. Med-
ical care, including HAART, is tax-paid and provided
free-of-charge to all PLHIV. Treatment of HIV is re-
stricted to eight specialized medical centres. Six of these
centres (treating 97 % of Danish PLHIV) (Copenhagen
University Hospital, Hvidovre, (HVH), Skejby, Aarhus
University Hospital (AUH), Copenhagen University
Hospital, Rigshospitalet (RH), Odense University Hos-
pital (OUH), Aalborg University Hospital (AAUH), and
Nordsjællands Hospital Hillerød (HIH)) participated in
SHADE (see below).
The SHADE cohort
The SHADE cohort is an ongoing, multicentre, pro-
spective, observational cohort study of WLWH in
Denmark attending regular outpatient care for their HIV
infection. Study participants were consecutively enrolled
during their outpatient visits from 1 February 2011 to 1
February 2012 and followed-up after 6 months. The
study focuses on STIs, contraceptive choices, sexual ac-
tivity, cervical abnormalities and cancer, human papillo-
mavirus (HPV) infection, HIV disclosure and other
aspects of living with HIV as a woman.
Study population
WLWH in Denmark attending care in one of the Danish
HIV centres. Inclusion criteria were HIV-1 infection
and ≥ 18 years of age. Exclusion criteria were pregnancy,
alcohol- or drug abuse impeding adherence to the
protocol.
Interview survey
Standardized interview questions were developed in con-
sultation with clinical specialists and a statistician and
appropriate revisions were made after a pilot study in-
cluding ten HIV-negative volunteers. Questions were in
Danish and closed-ended (Additional file 1 and Add-
itional file 2; questionnaires in English). Double manual
data entry of the questionnaires was performed, using
the EpiData Entry program [11].
Trained doctors performed the standardized inter-
views regarding weight/height, tobacco and alcohol con-
sumption, lifetime sexual partners, history of herpes and
condyloma, symptoms from the lower abdomen, HPV
vaccination status, adherence to HAART, and use of
contraceptives.
At 6-month follow-up a similar interview regarding
marital status, partner’s HIV status, sexual activity within
the past 6 months, practice of anal sex, and possible rea-
sons for no condom use was performed.
Registries
The Civil Registration System (CRS)
The CRS is a national registry of all Danish residents
[12]. A 10-digit personal identification number (PIN) is
assigned to each individual at birth or immigration. The
PIN was used as a linkage to the Danish HIV Cohort
Study (DHCS).
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Danish HIV Cohort Study (DHCS)
The DHCS is a prospective, observational, nationwide
cohort study of all PLHIV seen at the Danish HIV clinics
since 1January 1995 [13]. Data collection is ongoing,
with continuous enrolment of newly diagnosed PLHIV.
The database is updated annually and contains extensive
data on demographics, date of HIV diagnosis, laboratory
results etc.
Microbiological testing
Chlamydia trachomatis (CT) and Neisseria gonorrhoeae
(NG)
Samples were analysed according to local guidelines at
the local departments of microbiology. At HVH, a BD
ProbeTec ET Wet Swab was used for detection of CT
and NG on oral, cervical, anal and first-void urine speci-
mens (for the latter using the BD ProbeTec Urine Pre-
servative Transport Kit (UPT)). At AAUH and RH,
cervical and urethral specimens were examined for CT
with a COBAS® Taqman® 48 analyzer (Roche Molecular
Diagnostics, Indianapolis, IN, USA). Further, cervical,
anal, urethral and oral specimens were obtained for cul-
ture of NG with charcoal swabs and transported in
Stuart medium (SSI Diagnostica, Hillerød, Denmark).
On specimens from AUH, OUH and HIH, the Gen-
Probe Panther Aptima Combo2 test (San Diego, USA)
was used for detection of CT and NG.
Syphilis
Until 1 July 2011 [14], syphilis serology was centralised at
Statens Serum Institut (SSI) (the National Institute for
Health Data and Diseases Control). Two non-treponemal
tests were used; Wassermann’s reaction (WR) was done
with a complement fixation technique, and rapid plasma
reagin (RPR) was determined by agglutination [3]. Trepo-
nemal tests were performed on seroreactive samples [3].
After 1 July 2011 syphilis serology was decentralised to
the local departments of microbiology performing a trepo-
nemal test detecting specific IgG and/or IgM antibodies to
Treponema pallidum using the ADVIA Centaur® Syphilis
assay (Siemens, US), the Syphilis TPA, from Vitros’
Immunodiagnostics, Ortho Clinical Diagnostics (High
Wycombe, UK) or the Architect Syphilis TP (Abbott
Japan, Japan: AST). If the antibody test was positive, non-
treponemal tests (WR/RPR) were sent to SSI for confirm-
ation. Patient files were examined regarding prior syphilis
infection and treatment.
Herpes Simplex 1 and 2 (HSV-1 and HSV-2)
Diagnosis of HSV-1 and 2 was conducted at Department
of Pathology, HVH. WLWH were swabbed once at entry
and cervical samples were examined by the CLART
Entherpex PCR (Genomica, Madrid, Spain). DNA ex-
traction was done using the MagNAPure LC96 (Roche
Molecular Systems, Rotkreuz, Ch). Samples showing an
invalid outcome were retested, and the second result
was considered definitive.
HIV RNA
Undetectable viral load was defined as a plasma HIV
RNA load of <40 copies/mL, which was the highest level
of sensitivity for testing in the observation period.
Ethics, consent and permissions
At entry, written and oral informed consent was ob-
tained from all participants. The study and the DHCS
were approved by the Danish Data Protection Agency
(2015–231–0126, 2012–58–0004 and 2012–41–0005).
Further, the study was approved by the Danish Regional
Committee on Health Research Ethics (approval num-
bers: H–3–2010–119 and H–2–2014–102).
Statistical analyses
Continuous variables were summarized as median and
interquartile ranges (IQR) and compared using Wilcoxon
rank sum test. Categorical variables were reported as
counts and percentages and compared by chi-square test
or Fisher’s exact test as appropriate.
To calculate age and follow-up time for participants in
the study and WLWH in the remaining DHCS 1
February 2012 (the last possible day of inclusion) was
defined as day of inclusion.
Multivariate logistic regression analyses were per-
formed to identify predictors of condom use in sexually
active WLWH attending 6-month follow-up. Odds ratios
(ORs) and 95 % confidence intervals (CI) were estimated
and adjusted for seven candidate predictor variables
chosen a priori, including age, race, HIV-RNA at inclu-
sion, number of lifetime sexual partners, marital status,
partner’s HIV status, and self-reported HSV infection
prior to inclusion. To control for repeated testing, a
combined p-value was estimated for variables spending
more than one degree of freedom in the logistic
regression.
Individuals with missing explanatory values were ex-
cluded from the multivariate regression analyses. The
validity of the model was tested using the Hosmer and
Lemeshow Goodness-of-Fit Test.
SAS statistical software version 9.3 (SAS Institute
Inc., Cary, NC, USA) was used for data analysis and
p-values <0.05 (two-sided) were considered statistically
significant.
Results
Of the 1,392 WLWH alive and ≥18 years of age in the
DHCS, 334 (24 %) consented to participate in the study
(Fig. 1). At inclusion, median age was 42.5 years com-
pared to 42.0 years (p = 0.22) in the remaining WLWH
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in the DHCS and HIV duration was 11.3 years compared
to 10.6 years (p = 0.097) (Table 1). Other baseline char-
acteristics are presented in Table 1.
Sexually transmitted infections
At entry, four (1 %) women presented with CT
(Table 1). Two of these reported condom use and
two had lower abdominal symptoms. No participants
tested positive for NG (Table 1). Positive serologic
syphilis tests were found in eight (2 %) participants;
all were interpreted as past infections; 7 (88 %) of
these women were immigrants (Table 1). A history of
genital herpes infection was stated by 64 (19 %). No
participants were HSV-1 PCR positive, but six (2 %)
tested HSV-2 positive by PCR; of whom all were on
HAART (Table 1). The prevalence of STIs was too
low to perform adjusted analyses aiming at predicting
associated factors.
Use of contraceptives – 6 month follow-up
A total of 252 (76 % of the SHADE cohort) women
attended the 6 month follow-up (Fig. 1). Median time
from inclusion to follow-up was median 6.2 (IQR 5.9–7.4)
months. At follow-up, 168 (69 %) reported sexual activity
in the past 6 months - of these 165 (65 %) responded to
the question regarding contraceptive use (Table 2). Over-
all, 124 (75 %) of the sexual active women used contracep-
tives (Table 2). Among the 41 women using no
contraceptives, 29 were of reproductive age (<50 years)
and 10 of these stated a desire for pregnancy – leaving 19
(13 % of the sexually active WLWH in the reproductive
age) without birth control.
Condom use alone or as part of dual protection were
stated by 102 (62 %) participants (Table 2). Having an
HIV-negative partner predicted condom use (OR 3.89
(95 % CI 1.49–10.11)) (Table 3). A sensitivity analysis of
the adjusted analysis was performed to check for the ef-
fect of missing values on outcome by adding an extra
category with missing values. This had no impact on the
estimates.
Fifteen (9 %) of the sexually active women reported
use of hormonal contraception (HC) alone or as part
dual protection; of these; 14 were on HAART and 13
(93 %) received a regimen containing either efavirenz,
nevirapine, etravirine, atazanavir/ritonavir or darunavir/
ritonavir with possible drug-drug interactions with HC.
Discussion
In this multicenter, prospective, observational cohort of
WLWH in Denmark, we found a low prevalence of STIs
thus questioning the need for annual STI screening in
WLWH as recommended by e.g. the EACS guidelines
[6]. The majority of sexually active WLWH used con-
doms; primarily when being in a discordant relationship.
More than 10 % of sexually active WLWH in the repro-
ductive age were at risk of unintended pregnancy. Fi-
nally, the majority of WLWH on both HAART and HC
received a combination with potential drug-drug interac-
tions that could decrease contraceptive efficacy.
WLWH in SHADE was no different from WLWH in
the remaining nationwide DHCS with regards to age,
HIV and race, however they were more likely to be sexu-
ally infected with HIV, having a higher CD4 count and a
greater probability of being on HAART with a sup-
pressed viral load. We attribute these differences to the
exclusion criteria regarding drug abuse.
The viral load of HIV in plasma is a major determinant
of HIV transmission [15] and the correlation between
plasma and genital viral load is strong [1, 15]. Genital HIV
shedding is also influenced by local factors such as genital
ulcers, CT, NG and HSV [5, 15–17]. The increased inci-
dences of STIs in Western cohorts of PLHIV [3, 4] is
therefore of concern. Especially, asymptomatic STIs are
Eligible women in 
the DHCS
n=1,392
Women in the 
SHADE cohort
n=334
Not included
n=1,058
Attending
6-month follow-up
n=252
Failed to attend
6-month follow-up
n=82
Fig. 1 Flowchart of women in the Danish HIV Cohort Study (DHCS)
and the SHADE cohort
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Table 1 Baseline characteristics and prevalence of sexually transmitted infections in women living with HIV (WLWH) in the study
and WLWH in the remaining Danish HIV Cohort Study (DHCS)
WLWH in the study WLWH in the remaining DHCS p-value
Number of individuals 334 (24.0) 1,058 (76.0) NA1
Follow-up (years), median (IQR) 11.3 (5.9–16.9) 10.6 (5.5–15.9) 0.097
Follow-up time, total (person-years) 3,853 11,183 NA1
Age at inclusion, median (IQR), (years) 42.5 (36.8–48.3) 42.0 (35.5–48.2) 0.22
Race, n (%)
White 141 (42.6) 398 (39.5) 0.0412
Asian 44 (13.3) 114 (11.3)
Black 143 (43.2) 461 (45.7)
Other (missing) 3 (0.9) 35 (3.5)
(3) (50)
Place of HIV transmission, n (%) 114 (37.8) 326 (34.8) 0.11
Denmark 27 (8.9) 77 (8.2)
Europe + US 128 (42.4) 416 (44.4)
Africa 33 (10.9) 101 (10.8)
Asia 0 (0) 17 (1.8)
Other (missing) (32) (121)
Mode of transmission, n (%)
Heterosexual 294 (91.6) 799 (83.6) 0.0015
IDU 16 (5.0) 106 (11.1)
Other (missing) 11 (3.4) 51 (5.3)
(13) (102)
CD4 count at inclusion (cells/μL), n (%)
<200 12 (3.9) 79 (9.1) 0.012
200–350 51 (16.5) 138 (15.9)
>350 247 (79.7) 650 (75.0)
(missing) (24) (191)
HAART at inclusion), n (%)
Yes 317 (94.9) 866 (81.8) <0.0001
No 17 (5.1) 192 (18.2)
(missing) (0) (0)
On HAART with HIV RNA < 40 copies/mL), n (%)
Yes 250 (83.6) 576 (75.5) 0.0042
No 49 (16.4) 187 (24.5)
(missing) (18) (103)
Lifetime sexual partners, n (%)
<5 99 (29.6) -3 NA1
5–14 135 (40.4)
15–25 45 (13.5)
>25 53 (15.9)
Does not wish to respond 2 (0.6)
(missing) (0)
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worrying due to complications related to the STI in ques-
tion and rise in HIV infectiousness [5]. In WLWH, how-
ever, data on STIs, contraceptive choices, and sexual
health are scarce [4, 8].
Sexually transmitted infections
Only four (1 %) participants presented with CT, two of
whom had symptoms. No participants were diagnosed
with NG. In comparison, the point prevalence of CT and
NG in WLWH has been reported to be 1–27 % in stud-
ies carried out in the Western setting, with the highest
prevalence found in cohorts of young, newly diagnosed
WLWH [5, 18]. The long median HIV duration of
11 years in the present cohort impedes comparison of
these studies. Interestingly, an older Danish study on the
general population found a comparable prevalence of
CT <2 % in women older than 32 years of age and <1 %
in women older than 43 years of age [19].
The increasing rates of syphilis in MSM living with
HIV suggest a sexual high-risk behaviour [3] that is not
prevalent amongst WLWH in this study. Whereas more
than 70 % of women reported <15 lifetime sexual
Table 1 Baseline characteristics and prevalence of sexually transmitted infections in women living with HIV (WLWH) in the study
and WLWH in the remaining Danish HIV Cohort Study (DHCS) (Continued)
History of genital herpes infection, n (%)
Yes 64 (19.2) -3 NA1
No 227 (68.0)
Unknown 43 (12.8)
(missing) (0)
Symptoms from the lower abdomen, n (%)
Yes 78 (23.3) -3 NA1
No 237 (71.0)
Does not wish to respond 19 (5.7)
(missing) (0)
Outline of specific symptoms from the lower abdomen, n (% of women stating “yes” to lower abdominal symptoms)
Vaginal discharge 30 (38.5) -3 NA1
Burning sensation when urinating 8 (10.3)
Abnormal menstrual bleeding 24 (30.8)
Bleeding during sexual intercourse 6 (7.7)
Pain while at rest 9 (11.5)
Pain during sexual intercourse 15 (19.2)
Other 34 (43.6)
Chlamydia trachomatis infection, n (%)4,5 4 (1.2) -3 NA1
Cervical 3
Urethral 3
Neisseria gonorrhoeae infection, n (%)6 0 (0) -3 NA1
Cervical 0
Urethral 0
Rectal 0
Pharyngeal 0
Syphilis, n (%)7
Any positive serologic test 8 (2.5) -3 NA1
Positive serology requiring treatment 0 (0)
HSV-1 infection, n (%)8,9 0 (0) -3 NA1
HSV-2 infection, n (%)8,9 6 (1.9) -3 NA1
1 NA = not applicable, 2 There was no difference in distribution of race between groups if the category “other” was removed from the “Race” variable (p = 0.45),
3 No information available, 4 2/334 had no Chlamydia trachomatis sample, 5 Some patients were positive for Chlamydia in more than one anatomical location,
6 1/334 had no Neisseria gonorrhoeae sample, 7 9/334 had no syphilis test available, 8 HSV = Herpes simplex virus, 9 16/334 had no sample for herpes simplex virus
type-1 or -2
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partners, this number is markedly higher in MSM co-
horts [20]. Also, compared to international female HIV
cohorts the number is low; in the Women’s Interagency
HIV Study (WIHS) 31 % had 10–49 lifetime sexual part-
ners and 24 % reported >50 sexual partners [21]. The
prevalence of syphilis in cohorts of WLWH in Western
settings is 2–13 % - peaking amongst newly diagnosed
WLWH [5]. In the present study no syphilis cases were
seen, however, the majority of WLWH presenting with
positive syphilis serology indicating a prior infection
were immigrants, which suggests a lower threshold for
screening in this subgroup.
Up to half of all newly diagnosed PLHIV demonstrate
HSV-2 infection, which has been ascribed to the associ-
ation between ulcerative STIs and HIV [22]. Here, more
than 40 % of participants reported to be infected with
HIV in Africa, where HIV and HSV co-infection is
highly prevalent [23]. Yet, no women were tested posi-
tive by PCR of HSV-1 and only 2 % tested PCR positive
for HSV-2, while about one fifth reported a history of
genital herpes infection. All participants shedding HSV-
2 were on HAART, which is in line with studies finding
no attenuation of HSV-2 reactivation in individuals on
suppressive HAART [24]. In studies of HSV-2 seroposi-
tive WLWH, a markedly higher prevalence of 11–23 %
of HSV-2 shedding were found [24, 25].
Use of contraceptives
Studies on contraceptive use in WLWH are strikingly
scarce [8, 26]. The proportion of participants reporting
use of any contraceptive method was higher in the study
group, than the estimated proportion of contraceptive
use in developed regions of the world and the global
proportion in 2011; 75 %, 70 % and 63 %, respectively
[27]. However, >10 % of sexually active participants were
in the reproductive age, had no pregnancy desire, and
nonetheless used no birth control.
Though, the number of lifetime sexual partners was
low compared to the WIHS, the number of women
reporting to be sexually active in the past 6 months was
comparable at around 70 % [21]. Preferred contracep-
tives were condoms used by 62 % of sexually active
women. In comparison, 26–80 % reported using a bar-
rier contraceptive method at least intermittently in co-
horts of young PLHIV [18, 28, 29]. Condom use in the
present study was predicted by having an HIV-negative
partner.
The metabolism of both HC and some non-nucleoside
reverse-transcriptase inhibitors (NNRTIs) and protease
inhibitors (PIs) is dependent on the cytochrome P450
system in the liver [7, 26]. The NNRTIs efavirenz and
nevirapine both decrease effectiveness of HC [7], while
no dose adjustment is needed for rilpivirine, etravirine
can be co-administered with 35 μg estrogen [7]. Pre-
scription of PIs boosted with ritonavir is not recom-
mended in combination with HC with the exception of
atazanavir, which however requires a dose of at least
30 μg estrogen [7]. In the present study, 13 out of 14
participants on both HAART and HC were on a regimen
with possible drug-drug interactions and therefore at
risk of reduced contraceptive efficacy.
The strengths of this study include the prospective na-
ture and the use of validated laboratory tests. Addition-
ally, the standardized methods of data collection and the
Table 2 Characteristics on marital status, sexual activity and
contraception at 6-month follow-up (n = 252)
WLWH in the study
Marital status, n (%)
Married 105 (43.0)
Cohabitating 35 (14.3)
Regular partner (not cohabitating) 27 (11.1)
Single 77 (31.6)
(missing) (8)
Partner’s HIV status, n (%)
HIV-positive 50 (29.1)
HIV-negative 118 (68.6)
Not tested/do not know 4 (2.3)
(missing) (80)
Sexual activity in the past 6 months, n (%)
Yes 168 (68.6)
No 77 (31.4)
(missing) (7)
Current use of contraception in sexually active women, n (%)
Condom 84 (50.9)
Condom+ hormonal contraception 6 (3.6)
Condom+ intra uterine device 1 (0.6)
Condom+ sterilization 11 (6.7)
Hormonal contraception 9 (5.5)
Intra uterine device 5 (3.0)
Sterilization 6 (3.6)
Other 2 (1.2)
Nothing 41 (24.9)
(missing) (3)
Reasons for no condom use in sexually active women, n (%)1,2
Patient’s wish 2 (3.2)
Partner’s wish 11 (17.7)
Joint decision 25 (40.3)
Partner has HIV 23 (37.1)
Attempts to become pregnant 10 (16.1)
HIV RNA is low 13 (21.0)
1More than one answer allowed, n (%) does not add up to 100 %, 2N (% of
women responding to the specific question)
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Table 3 Unadjusted and adjusted odds ratios for predictors of condom use in sexually active women stating use of contraception
at 6-month follow-up (n = 165)
Predictors of condom use No condom use
(n = 63)
Condom use
(n = 102)
Unadjusted odds ratios p-value Mutually adjusted
odds ratios1
p-value
Age at 1 February 2011 (inclusion), (years)
>50 15 (57.7) 11 (42.3) 1.00 – 1.00 –
30–49 44 (34.9) 82 (65.1) 2.54 (1.08–6.00) 0.034 2.30 (0.66–7.99) 0.19
18–29 4 (30.8) 9 (69.2) 3.07 (0.75–12.59) 0.12 1.14 (0.11–11.54) 0.91
(missing) (0) (0)
Combined p-value 0.089 0.36
Race, n (%)
White 27 (38.6) 43 (61.4) 1.00 – 1.00 –
Asian 11 (45.8) 13 (54.2) 0.74 (0.29–1.89) 0.53 0.62 (0.19–2.07) 0.44
Black 24 (34.3) 46 (65.7) 1.20 (0.60–2.40) 0.60 0.66 (0.25–1.72) 0.39
(missing) (1) (0)
Combined p-value 0.60 0.64
HIV RNA at inclusion, n (%)2
Undetectable 45 (35.2) 83 (64.8) 1.00 – 1.00 –
Detectable 13 (54.2) 11 (45.8) 0.46 (0.19–1.11) 0.083 0.86 (0.30–2.49) 0.78
(missing) (5) (8)
Combined p-value 0.083 0.78
Lifetime sexual partners at inclusion, n (%)
<4 22 (47.8) 24 (52.2) 1.00 – 1.00 –
5–14 25 (36.8) 43 (63.2) 1.58 (0.74–3.37) 0.24 1.40 (0.52–3.79) 0.51
15–25 9 (34.6) 17 (65.4) 1.73 (0.64–4.68) 0.28 0.94 (0.23–3.80) 0.93
>25 7 (28.0) 18 (72.0) 2.36 (0.83–6.72) 0.11 0.96 (0.23–4.00) 0.96
(missing) (0) (0)
Combined p-value 0.38 0.85
Marital status, n (%)
Married 35 (41.2) 50 (58.8) 1.00 – 1.00 –
Cohabitating 17 (53.1) 15 (46.9) 0.62 (0.27–1.40) 0.25 0.55 (0.20–1.50) 0.24
Regular partner (not cohabitating) 8 (33.3) 16 (66.7) 1.40 (0.54–3.63) 0.49 1.01 (0.31–3.23) 0.99
Single 3 (12.5) 21 (87.5) 4.90 (1.36–17.70) 0.015 – 0.99
(missing) (0) (0)
Combined p-value 0.030 0.67
Partner’s HIV status, n (%)
HIV-positive 30 (68.2) 14 (31.8) 1.00 – 1.00 –
HIV-negative 27 (28.7) 67 (71.3) 5.32 (2.45–11.55) <0.000 3.89 (1.49–10.11) 0.0054
Not tested/do not know 2 (50.0) 2 (50.0) 2.14 (0.27–16.81) 1 1.01 (0.05–19.87) 0.99
(missing) (4) (19) 0.47
Combined p-value 0.0001 0.014
Selfreported HSV3 infection prior to inclusion, n (%)
Yes 14 (43.8) 18 (56.2) 1.00 – 1.00 –
No 40 (36.0) 71 (64.0) 1.38 (0.62–3.07) 0.43 1.75 (0.66–4.63) 0.26
Do not know (missing) 9 (40.9) 13 (59.1) 1.12 (0.37–3.38) 0.84 1.63 (0.43–6.25) 0.47
Combined p-value 0.70 0.53
1The validity of the model was tested using the Hosmer and Lemeshow Goodness-of-Fit Test, 2HIV-RNA <40 copies/ml, 3HSV = Herpes simplex virus infection
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performance of double manual data entry enhanced ac-
curacy of data input and integrity of the interview re-
sults. Lastly, the ability to link to the nationwide,
complete DHCS with basic data on all PLHIV in
Denmark optimises results.
Limitations of the study were that women were only
recruited on days where nurses or doctors responsible of
the study were present in the outpatient clinic. However,
due to the DHCS differences between groups can be ad-
dressed. Though, we present a low point prevalence of
STIs, incidence of STIs in this cohort has not been ex-
amined. Finally, self-reported data especially on sexual
history may be unreliable [30].
Conclusion
Overall, the prevalence of STIs in WLWH in Denmark
was low. Screening for STIs at entry of HIV care may
prove valuable as shown by other cohorts [5] and due to
the fact that especially immigrants presented with posi-
tive syphilis serology indicating prior infection. However,
annual screening for STIs in WLWH attending routine
HIV care is of questionable value. Three quarters of
sexually active WLWH used contraception. Condoms
were preferred contraceptives, especially when having an
HIV-negative partner. The majority of WLWH receiving
both HAART and HC were on a regimen with possible
drug-drug interactions with ensuing risk of decreased
contraceptive efficacy. The discrepancy between the low
rates of STIs and the rather low proportion of condom
use can probably be explained by the relatively low num-
ber of lifetime sexual partners in this cohort. In our
opinion, there is an unmet need for contraceptive coun-
selling in WLWH.
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Additional file 1: Questionnaire 1. (DOC 126 kb)
Additional file 2: Questionnaire 2. (DOC 123 kb)
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